|
Demographic and clinical characteristics
|
|
Male—no. (%)
|
112 (81%)
|
50 (81%)
|
62 (82%)
|
1.00
|
|
Median age, years (IQR)
|
59 (48–67)
|
60 (51–67)
|
60 (52–67)
|
0.64
|
|
Immunocompromized patient—no. (%)
|
20 (14%)
|
9 (14%)
|
11 (14%)
|
1.00
|
|
Diabetes—no. (%)
|
43 (31%)
|
19 (31%)
|
24 (32%)
|
1.00
|
|
Hypertension—no. (%)
|
56 (41%)
|
19 (31%)
|
37 (49%)
|
0.049
|
|
Chronic respiratory failure—no. (%)
|
4 (3%)
|
2 (3%)
|
2 (3%)
|
1.00
|
|
Chronic kidney failure—no. (%)
|
7 (5%)
|
3 (5%)
|
4 (5%)
|
1.00
|
|
Median BMI, kg/m2 (IQR)
|
29 (26–33)
|
27 (26–33)
|
29 (25–33)
|
0.59
|
|
Median SAPS II (IQR)
|
36 (26–46)
|
35 (26–45)
|
36 (27–47)
|
0.62
|
|
Median time from onset symptoms to ICU admission, days (IQR)
|
10 (8–13)
|
8 (8–13)
|
10 (8–13)
|
0.002
|
|
Respiratory finding
|
|
Median 02 flow, liter/minute (IQR)
|
9 (4–12)
|
6 (5–13)
|
9 (6–15)
|
0.003
|
|
Median PaO2, mmHg (IQR)
|
71 (64–84)
|
71 (63–85)
|
69 (63–82)
|
0.45
|
|
Median respiratory rate, (IQR)
|
30 (27–35)
|
30 (26–35)
|
33 (28–36)
|
0.018
|
|
Median O2 maximal flow rate, Liter/minute, (IQR)
|
12 (9–15)
|
12 (9–15)
|
12 (9–15)
|
0.049
|
|
Laboratory finding
|
|
Median Lymphocyte, G/L (IQR)
|
0.8 (0.6–1.1)
|
0.9 (0.6–1.1)
|
0.8 (0.6–1.0)
|
0.10
|
|
Median Fibrinogen, g/L (IQR)
|
6.59 (5.9–7.3)
|
6.57 (6.0–7.3)
|
6.7 (6.2–7.3)
|
0.50
|
|
Median Phosphor, mmol/L (IQR)
|
0.82 (0.69–0.95)
|
0.8 (0.71–0.94)
|
0.84 (0.70–0.94)
|
0.29
|
|
Median CRP, mmol/L (IQR)
|
182 (114–263)
|
182 (106–262)
|
182 (125–269)
|
0.64
|
|
Median ferritin, µg/L (IQR)
|
1502 (874–2530)
|
1137 (880–2495)
|
1701 (885–2677)
|
0.036
|
|
Chest CT scan finding
|
|
Median ground glass surface, % (IQR)
|
50 (25–60)
|
50 (25–60)
|
50 (25–60)
|
0.27
|
|
Steroids during ICU stay—no.(%)
|
66 (48%)
|
25 (40%)
|
41 (54%)
|
0.15
|
